Protein kinase Cβ as a therapeutic target stabilizing blood-brain barrier disruption in experimental autoimmune encephalomyelitis

Tobias V. Lanz, Simon Becker, Matthias Osswald, Stefan Bittner, Michael K. Schuhmann, Christiane A. Opitz, Sadanand Gaikwad, Benedikt Wiestler, Ulrike M. Litzenburger, Felix Sahm, Martina Ott, Simeon Iwantscheff, Carl Grabitz, Michel Mittelbronn, Andreas Von Deimling, Frank Winkler, Sven G. Meuth, Wolfgang Wick, Michael Platten*

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

42 Citations (Scopus)

Abstract

Disruption of the blood-brain barrier (BBB) is a hallmark of acute inflammatory lesions in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis. This disruption may precede and facilitate the infiltration of encephalitogenic T cells. The signaling events that lead to this BBB disruption are incompletely understood but appear to involve dysregulation of tight-junction proteins such as claudins. Pharmacological interventions aiming at stabilizing the BBB in MS might have therapeutic potential. Here, we show that the orally available small molecule LY-317615, a synthetic bisindolylmaleimide and inhibitor of protein kinase Cβ, which is clinically under investigation for the treatment of cancer, suppresses the transmigration of activated T cells through an inflamed endothelial cell barrier, where it leads to the induction of the tight-junction molecules zona occludens-1, claudin 3, and claudin 5 and other pathways critically involved in transendothelial leukocyte migration. Treatment of mice with ongoing experimental autoimmune encephalomyelitis with LY-317615 ameliorates inflammation, demyelination, axonal damage, and clinical symptoms. Although LY-317615 dose-dependently suppresses T-cell proliferation and cytokine production independent of antigen specificity, its therapeutic effect is abrogated in a mouse model requiring pertussis toxin. This abrogation indicates that the anti-inflammatory and clinical efficacy is mainly mediated by stabilization of the BBB, thus suppressing the transmigration of encephalitogenic T cells. Collectively, our data suggest the involvement of endothelial protein kinase Cβ in stabilizing the BBB in autoimmune neuroinflammation and imply a therapeutic potential of BBB-targeting agents such as LY-317615 as therapeutic approaches for MS.

Original languageEnglish
Pages (from-to)14735-14740
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume110
Issue number36
DOIs
Publication statusPublished - 3 Sept 2013
Externally publishedYes

Keywords

  • CNS
  • EAE
  • Enzastaurin

Fingerprint

Dive into the research topics of 'Protein kinase Cβ as a therapeutic target stabilizing blood-brain barrier disruption in experimental autoimmune encephalomyelitis'. Together they form a unique fingerprint.

Cite this